Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Royce & Associates LP

Royce & Associates LP cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) by 79.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,810 shares of the specialty pharmaceutical company’s stock after selling 204,314 shares during the period. Royce & Associates LP’s holdings in Supernus Pharmaceuticals were worth $1,739,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SUPN. UMB Bank N A MO acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $29,000. First Horizon Advisors Inc. boosted its position in shares of Supernus Pharmaceuticals by 1,275.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,486 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 1,378 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $43,000. FDx Advisors Inc. acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $205,000. Finally, Nisa Investment Advisors LLC boosted its position in shares of Supernus Pharmaceuticals by 73.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 2,803 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, April 18th. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,000 shares of the company’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $32.98, for a total value of $164,900.00. Following the transaction, the vice president now owns 87,220 shares of the company’s stock, valued at $2,876,515.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.99% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Stock Performance

SUPN opened at $32.16 on Friday. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 24.74 and a beta of 1.04. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.00 and a quick ratio of 1.69. Supernus Pharmaceuticals, Inc. has a 1-year low of $23.15 and a 1-year high of $34.50. The business has a 50 day moving average price of $29.18 and a two-hundred day moving average price of $29.81.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last released its earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.15). The firm had revenue of $170.10 million during the quarter, compared to analyst estimates of $164.23 million. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same quarter last year, the company earned $0.43 earnings per share. Research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.64 EPS for the current fiscal year.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

See Also

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.